These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 2553248)
1. Altered formation of DNA in human cells treated with inhibitors of DNA topoisomerase II (etoposide and teniposide). Lönn U; Lönn S; Nylen U; Winblad G Cancer Res; 1989 Nov; 49(22):6202-7. PubMed ID: 2553248 [TBL] [Abstract][Full Text] [Related]
2. Expression of protein-associated DNA damage in the alkaline elution assay in the absence of enzymatic deproteinization. Gewirtz DA; Ellis AL; Randolph JK; Yanovich S; Swerdlow PS; Povirk LF; Yalowich JC Cancer Commun; 1989; 1(3):175-80. PubMed ID: 2561738 [TBL] [Abstract][Full Text] [Related]
3. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity. Kerrigan D; Pommier Y; Kohn KW NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238 [TBL] [Abstract][Full Text] [Related]
4. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888 [TBL] [Abstract][Full Text] [Related]
5. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Long BH; Musial ST; Brattain MG Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Beck WT; Danks MK Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118 [TBL] [Abstract][Full Text] [Related]
7. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity. Qiu J; Catapano CV; Fernandes DJ Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211 [TBL] [Abstract][Full Text] [Related]
8. [Mechanisms of resistance to DNA topoisomerase II inhibitors]. Kohno K; Takano H; Kuwano M Gan To Kagaku Ryoho; 1991 Aug; 18(10):1568-73. PubMed ID: 1651684 [TBL] [Abstract][Full Text] [Related]
9. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26. Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414 [TBL] [Abstract][Full Text] [Related]
10. DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition. Chow KC; Macdonald TL; Ross WE Mol Pharmacol; 1988 Oct; 34(4):467-73. PubMed ID: 2845248 [TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202 [TBL] [Abstract][Full Text] [Related]
12. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. Yang L; Rowe TC; Liu LF Cancer Res; 1985 Nov; 45(11 Pt 2):5872-6. PubMed ID: 2996763 [TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205 [TBL] [Abstract][Full Text] [Related]
14. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Jensen PB; Sørensen BS; Sehested M; Grue P; Demant EJ; Hansen HH Cancer Res; 1994 Jun; 54(11):2959-63. PubMed ID: 8187081 [TBL] [Abstract][Full Text] [Related]
15. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. Lelièvre S; Benchokroun Y; Larsen AK Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278 [TBL] [Abstract][Full Text] [Related]
16. Elevated topoisomerase II activity and altered chromatin in nitrogen mustard-resistant human cells. Tan KB; Mattern MR; Boyce RA; Hertzberg RP; Schein PS NCI Monogr; 1987; (4):95-8. PubMed ID: 2819739 [TBL] [Abstract][Full Text] [Related]
17. Studies of topoisomerase-specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide. Hwang JL; Shyy SH; Chen AY; Juan CC; Whang-Peng J Cancer Res; 1989 Feb; 49(4):958-62. PubMed ID: 2536295 [TBL] [Abstract][Full Text] [Related]
18. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Kaufmann SH Cancer Res; 1989 Nov; 49(21):5870-8. PubMed ID: 2790800 [TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells. Beere HM; Chresta CM; Hickman JA Mol Pharmacol; 1996 May; 49(5):842-51. PubMed ID: 8622634 [TBL] [Abstract][Full Text] [Related]
20. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Long BH; Musial ST; Brattain MG Cancer Res; 1985 Jul; 45(7):3106-12. PubMed ID: 3839166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]